Details for Patent: 8,415,345
✉ Email this page to a colleague
Which drugs does patent 8,415,345 protect, and when does it expire?
Patent 8,415,345 protects TAFINLAR and is included in two NDAs.
Protection for TAFINLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-nine patent family members in thirty-four countries.
Summary for Patent: 8,415,345
| Title: | Benzene sulfonamide thiazole and oxazole compounds |
| Abstract: | The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents. |
| Inventor(s): | Adjabeng; George (Durham, NC), Adams; Jerry Leroy (Collegeville, PA), Dickerson; Scott Howard (Durham, NC), Hornberger; Keith (Mount Sinai, NY), Johnson; Neil W. (Collegeville, PA), Kuntz; Kevin (Durham, NC), Petrov; Kimberly (Durham, NC), Ralph; Jeffrey M. (Collegeville, PA), Rheault; Tara Renae (Durham, NC), Schaaf; Gregory (Durham, NC), Stellwagen; John (Durham, NC), Tian; Xinrong (Collegeville, PA), Uehling; David E. (Durham, NC), Waterson; Alex G. (Durham, NC), Wilson; Brian (Durham, NC) |
| Assignee: | Glaxo SmithKline LLC (Philadelphia, PA) |
| Application Number: | 12/991,004 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; Process; |
More… ↓ |
Drugs Protected by US Patent 8,415,345
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-001 | May 29, 2013 | RX | Yes | No | 8,415,345*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-002 | May 29, 2013 | RX | Yes | Yes | 8,415,345*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Novartis | TAFINLAR | dabrafenib mesylate | TABLET, FOR SUSPENSION;ORAL | 217514-001 | Mar 16, 2023 | RX | Yes | Yes | 8,415,345*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,415,345
| PCT Information | |||
| PCT Filed | May 04, 2009 | PCT Application Number: | PCT/US2009/042682 |
| PCT Publication Date: | November 12, 2009 | PCT Publication Number: | WO2009/137391 |
International Family Members for US Patent 8,415,345
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 071617 | ⤷ Subscribe | |||
| Australia | 2009244491 | ⤷ Subscribe | |||
| Brazil | PI0912541 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
